Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (22925)	7/8/1998 10:45:00 AM
From: Machaon	Respond to of 32384

<< I do expect new coverage for LGND, which could produce a significant price rise (but I don't expect a short term double on the news). >> One factor that I feel was keeping a lid on biotechs, was the reduction in government funding, which made drug discovery more expensive. Yesterday, the news covered a story about generic drug prices, which are skyrocketing. For an example, they showed a supply, of generics, which would normally cost a druggist about $25, now costing about $250-$300. This is very unfortunate for us consumers. But, for the drug companies, this will supply significant new funds, providing that congress, who is looking into this price explosion, doesn't step in to try and restrict the price increases. Anyway....... the significant generic price increases should have an positive impact on drug company stock and the biotech companies, that could benefit from the increased availability of drug company funding, and the possible increased prices that they could get for their own new drugs. Regards, Bob